Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors

Yano,Akira; Shigematsu,Yoshinori; Kitano,Hiroyuki; Hanayama,Aki; Ozawa,Akira; Tacho,Takatoshi; Fujii,Motohiro

doi:10.3892/ol.2010.165

Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors

Authors:
- Akira Yano
- Yoshinori Shigematsu
- Hiroyuki Kitano
- Aki Hanayama
- Akira Ozawa
- Takatoshi Tacho
- Motohiro Fujii
View Affiliations

Affiliations: Department of Urology, Matsuyama Red Cross Hospital, Ehime 790-8524, Japan
Published online on: September 1, 2010 https://doi.org/10.3892/ol.2010.165
Pages: 1049-1054

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) are enzymes involved in nucleic acid metabolism. It has been reported (based on observations of various tumor types) that the extent of the mRNA expression of these enzymes within tumor tissues may be used as a factor to define tumor prognosis. It has also been reported that the mRNA expression patterns differ in each type of tumor. However, few reports are available on the distribution of mRNA expression in prostate cancers. This study was conducted on tissue specimens obtained from 172 patients who were diagnosed with prostate cancer and had undergone total prostatectomies. The mRNA expression of TS, DPD, OPRT and TP was quantitatively analyzed using the Danenberg tumor profile (DTP) method. The results were used to examine the correlations between the distributions of the mRNAs and clinicopathological factors, as well as the significance of their expression as a prognostic factor. Patients with poorly differentiated cancers in their tissues showed a significant increase in the mRNA expression of TS and OPRT. The increases in the TP mRNA content were proportional to an increase in the Gleason scores. The prognosis was significantly poorer in those cases with a high expression of TS or OPRT mRNA and a low expression of DPD mRNA. In conclusion, the expression levels of mRNAs for TS, DPD and OPRT among the enzymes related to nucleic acid metabolism are useful as prognostic factors in patients with prostate cancers.

View Figures

View References

1	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
2	Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:2203–2206. 1987.PubMed/NCBI
3	Van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 40:939–950. 2004.PubMed/NCBI
4	Danenberg PV: Thymidylate synthetase – a target enzyme in cancer chemotherapy. Biochim Biophys Acta. 473:73–92. 1977.
5	Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 6:1653–1664. 1988.PubMed/NCBI
6	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
7	Peters GJ, Laurensse E, Leyva A, Lankelma J and Pinedo HM: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 46:20–28. 1986.
8	Peters GJ, van Groeningen CJ, Laurensse EJ and Pinedo HM: A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer. 68:1903–1909. 1991. View Article : Google Scholar : PubMed/NCBI
9	Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD and Fukushima M: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 22:709–716. 2008.
10	Li Y, Mizutani Y, Shiraishi T, et al: Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy. Urology. 69:988–995. 2007. View Article : Google Scholar : PubMed/NCBI
11	Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissection. Science. 274:998–1001. 1996. View Article : Google Scholar : PubMed/NCBI
12	Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer. 91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
13	Ichikawa W, Takahashi T, Suto K, et al: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 119:1927–1933. 2006. View Article : Google Scholar : PubMed/NCBI
14	Hakamada Y, Tsuchida A, Arima M, et al: Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy. Int J Mol Med. 16:309–314. 2005.PubMed/NCBI
15	Miyoshi T, Kondo K, Toba H, et al: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res. 27:2641–2648. 2007.PubMed/NCBI
16	Etienne MC, Chéradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 13:1663–1670. 1995.PubMed/NCBI
17	Horiguchi J, Yoshida T, Koibuchi Y, et al: DPD activity and immunohistochemical DPD expression in human breast cancer. Oncol Rep. 11:65–72. 2004.PubMed/NCBI
18	Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.
19	Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 4:2371–2376. 1998.
20	Saito S, Tsuno N, Nagawa H, et al: Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer. 88:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
21	Ochiai T, Nishimura K, Noguchi H, et al: Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer. 118:3084–3088. 2006. View Article : Google Scholar
22	Ichikawa W, Uetake H, Shirota Y, et al: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 89:1486–1492. 2003. View Article : Google Scholar
23	Inoue T, Segawa T, Shiraishi T, et al: High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase. BJU Int. 98:197–200. 2006. View Article : Google Scholar : PubMed/NCBI